Lv48
622 积分 2025-09-18 加入
A Phase 2 Trial of Tobevibart plus Elebsiran in Hepatitis D
3天前
已完结
The HIF-2α/PPARα pathway is essential for liraglutide-alleviated, lipid-induced hepatic steatosis
5天前
已完结
Liraglutide Attenuates Hepatic Ischemia–Reperfusion Injury by Modulating Macrophage Polarization
5天前
已完结
Liraglutide and GLP-1(9–37) alleviated hepatic ischemia-reperfusion injury by inhibiting ferroptosis via GSK3β/Nrf2 pathway and SMAD159/Hepcidin/FTH pathway
5天前
已完结
Effect on HBs antigen clearance of addition of pegylated interferon alfa-2a to nucleos(t)ide analogue therapy versus nucleos(t)ide analogue therapy alone in patients with HBe antigen-negative chronic hepatitis B and sustained undetectable plasma hepatitis B virus DNA: a randomised, controlled, open-label trial
6天前
已完结
VIR-2218 (elebsiran) plus pegylated interferon-alfa-2a in participants with chronic hepatitis B virus infection: a phase 2 study
6天前
已完结
Liraglutide and GLP-1(9–37) alleviated hepatic ischemia-reperfusion injury by inhibiting ferroptosis via GSK3β/Nrf2 pathway and SMAD159/Hepcidin/FTH pathway
6天前
已完结
Defatting of Human Livers During Long-Term ex situ Normothermic Perfusion: Novel Strategy to Rescue Discarded Organs for Transplantation
6天前
已完结
Epigenetics in NAFLD/NASH: Targets and therapy
8天前
已完结
2020 position statement and recommendations of the European Liver and Intestine Transplantation Association (ELITA): management of hepatitis B virus‐related infection before and after liver transplantation
16天前
已完结
皖公网安备34019202002308
